Usage Examples
- The study is significant risk, so we cannot enroll until 30 days after FDA receives the IDE.
- The IRB accepted our non-significant risk rationale, so there is no IDE application to file.
- IDE data from the 400-patient pivotal trial is the clinical evidence core of the PMA.
What is Investigational Device Exemption (IDE)?
Investigational Device Exemption is FDA authorization to ship and use an uncleared or unapproved device in a clinical investigation, exempting it from premarket approval and performance-standard requirements while safety and effectiveness data is collected.
An Investigational Device Exemption exists to break a circular problem. A device that has not been cleared or approved cannot be shipped for commercial use, yet the clinical evidence a 510(k), De Novo, or PMA needs can only come from putting that device in patients. The IDE permits a device that would otherwise require premarket approval or a performance standard to be shipped lawfully, for investigation only.
An IDE covers the clinical investigation and nothing beyond it. The IDE carries no marketing rights, no promotional latitude, and no finding about the device's eventual approvability. It also does not displace the rest of the human-subject framework: investigations conducted under section 520(g) of the FD&C Act remain subject to the informed consent requirements of 21 CFR Part 50 and to IRB review, which run alongside Part 812 rather than inside it.
An IDE is applied through one upstream decision: whether the investigation is significant risk or non-significant risk. Significant risk studies require an application to FDA and cannot start until both FDA and each reviewing IRB have approved. Non-significant risk studies run under abbreviated requirements with the IRB alone, after the sponsor gives that IRB a written rationale for the classification.
Not to be confused with
- 510(k)
- a 510(k) is a marketing submission that puts a device on the market. An IDE only authorizes the study that generates the evidence; it is never itself a route to market.
- PMA
- a PMA is the approval decision for a Class III device. The IDE is the permission to run the pivotal trial the PMA will rest on. Two separate applications, two separate reviews, years apart.
- IND
- an IND covers investigational drugs and biologics under FD&C Act section 505(i). The IDE is the device-side instrument under section 520(g), governed by 21 CFR Part 812 rather than Part 312.
- NSR study
- a non-significant risk study is not "an IDE with less paperwork." No IDE application is ever filed with FDA; the abbreviated requirements of 21 CFR 812.2(b) apply instead, and the IRB is the only approving body.
The obligations depend on which side of the risk determination the study falls on.
What you must do
- 1Determine whether the investigational device is a significant risk device — an implant, a life-supporting device, a device of substantial importance in diagnosis or treatment, or one otherwise presenting a potential for serious risk to a subject21 CFR 812.3(m)
- 2Submit an IDE application to FDA if you intend to use a significant risk device in an investigation, or to conduct an investigation involving an exception from informed consent21 CFR 812.20(a)
- 3Do not begin the investigation until 30 days after FDA receives the application, unless FDA notifies the sponsor that the investigation may not begin21 CFR 812.30(a)
- 4Do not begin any investigation, or any part of one, until an IRB and FDA have both approved the relevant application or supplemental application21 CFR 812.42
- 5For a non-significant risk device, label the device per § 812.5 and obtain IRB approval after giving the reviewing IRB a brief explanation of why the device is not a significant risk device21 CFR 812.2(b)
Common mistakes
Self-declaring non-significant risk to skip the FDA submission
the classification is not the sponsor's to assert unilaterally; the IRB has to be given the rationale and has to agree. If it does not, the study was a significant risk investigation that needed an FDA application before the first subject, and every enrollment to that point was unauthorized.
Enrolling on the 30-day clock while an IRB is still reviewing
the 30-day rule and the dual-approval rule are separate. 21 CFR 812.42 bars starting an investigation, or any part of one, until both an IRB and FDA have approved. Sites routinely sit behind their local IRB after FDA is satisfied; enrolling there is a violation regardless of the FDA timeline.
Reading IDE authorization as a signal about approvability
it is permission to collect evidence, not a preview of the marketing decision. The 510(k), De Novo, or PMA review evaluates the resulting data on its own terms, and a cleanly executed IDE study can still produce evidence that fails to support the claim.
When This Matters
- The study is significant risk, so we cannot enroll until 30 days after FDA receives the IDE.
- The IRB accepted our non-significant risk rationale, so there is no IDE application to file.
- IDE data from the 400-patient pivotal trial is the clinical evidence core of the PMA.
Frequently Asked Questions
Significant risk devices need a full IDE application submitted to FDA plus IRB approval; non-significant risk devices need only IRB approval under the abbreviated requirements of 21 CFR 812.2(b). Significant risk means implants, life-supporting devices, or devices of substantial importance in diagnosis or treatment that present a potential for serious risk to subjects.
Related Use Cases
- Medical Devices Use Cases
Prepare 510(k), PMA, and De Novo submissions with AI-guided pathway selection
- Consulting Use Cases
Manage 15+ client programs from one dashboard with per-client workspaces and tracking
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
